Work

Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia

Year: 2015

Type: article

Source: Blood

DOI: 10.1182/blood.v126.23.2529.2529

Authors: Ce Shi, Lina Han, Qi Zhang, Kathryn G. Roberts, Eugene Park, Yoko Tabe, Rodrigo Omar Jacamo, Hong Mu, Shuo-Chieh Wu, Jin Zhou, Helen Ma, Zhihong Zeng, Nitin Jain, Elias J Jabbour, Markus Muschen, Sarah K Tasian, Charles G. Mullighan, David M. Weinstock, David Fruman, Marina Konopleva

Institutions: The University of Texas MD Anderson Cancer Center, Harbin Medical University, First Affiliated Hospital of Harbin Medical University, St. Jude Children's Research Hospital, University of Cambridge, Juntendo University, Dana-Farber Cancer Institute, University of California, San Francisco, Children's Hospital of Philadelphia, University of California, Irvine

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979996329

FWCI: 1.429

Cites:

Cited by: 4

Related to: 10